<PAGE>
================================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________
FORM 10-Q
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the quarterly period ended March 31, 2000
or
[_] TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT OF 1934
For the transition period from to
_____________
Commission file number 0-27914
RIBOZYME PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
_____________
Delaware 34-1697351
-------- ----------
(State of incorporation) (I.R.S. Employer Identification No.)
2950 Wilderness Place
Boulder, Colorado 80301
(Address of principal executive offices)
Registrant's telephone number: (303) 449-6500
_____________
Check whether the registrant: (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days.
Yes X No _____
-----
The number of shares of the registrant's common stock, par value $0.01 per
share, outstanding as of May 5, 2000 was 15,191,977.
<PAGE>
RIBOZYME PHARMACEUTICALS, INC.
INDEX TO FORM 10-Q
PART 1 - FINANCIAL INFORMATION PAGE
----
Item 1. Financial Statements
Condensed Balance Sheets as of March 31, 2000 (unaudited) and
December 31, 1999............................................ 3
Condensed Statements of Operations - Three Months Ended
March 31, 2000 and 1999 (unaudited).......................... 4
Condensed Statements of Cash Flows - Three Months Ended
March 31, 2000 and 1999 (unaudited).......................... 5
Notes to Condensed Financial Statements (unaudited).......... 6
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations.................................... 8
Item 3. Quantitative and Qualitative Disclosures About Market Risk... 14
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K............................. 14
SIGNATURES............................................................ 15
Exhibit Index......................................................... 16
2
<PAGE>
PART I. FINANCIAL INFORMATION
ITEM I. FINANCIAL STATEMENTS
RIBOZYME PHARMACEUTICALS, INC.
CONDENSED BALANCE SHEETS
<TABLE>
<CAPTION>
ASSETS
------
March 31, December 31,
2000 1999
------------ ------------
(unaudited)
<S> <C> <C>
Current assets
- --------------
Cash and cash equivalents $ 16,953,407 $ 9,749,822
Securities available-for-sale 1,097,466 4,250,259
Accounts receivable 2,186,280 1,545,164
Accounts receivable-related parties 1,477,038 484,729
Prepaid expenses and other current assets 574,234 256,571
------------ ------------
Total current assets 22,288,425 16,286,545
Property, plant and equipment at cost,
net of accumulated depreciation 3,559,106 3,803,906
Notes receivable-related parties 271,284 313,750
Patent costs, net 4,363,066 4,231,307
Investment in Medizyme 10,217,174 -
Other assets 456,591 456,591
------------ ------------
Total assets $ 41,155,646 $ 25,092,099
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------
Current liabilities
- -------------------
Accounts payable-trade $ 1,542,438 $ 974,309
Accrued expenses 758,025 626,153
Deferred revenue, current portion-related parties 400,000 400,000
Current portion of long-term debt 92,482 200,455
------------ ------------
Total current liabilities 2,792,945 2,200,917
Deferred revenue, long-term portion-related parties 1,100,003 1,200,001
Convertible debt-related parties 7,947,859 6,810,537
Stockholders' equity
- --------------------
Preferred stock 120 -
Common stock 120,115 112,633
Additional paid-in capital 117,042,008 98,894,100
Deferred compensation and other (42,317) (43,017)
Accumulated deficit (87,805,087) (84,083,072)
------------ ------------
Total stockholders' equity 29,314,839 14,880,644
------------ ------------
Total liabilities and stockholders' equity $ 41,155,646 $ 25,092,099
============ ============
</TABLE>
See notes to condensed financial statements
3
<PAGE>
RIBOZYME PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
Three months ended
March 31,
--------------------------
2000 1999
----------- -----------
<S> <C> <C>
Revenue
Collaborative agreements $ 2,539,571 $ 1,108,592
Collaborative agreements-related parties 1,330,295 592,643
----------- -----------
Total revenues 3,869,866 1,701,235
Expenses
Research and development 4,864,835 3,760,433
General and administrative 1,038,870 559,296
----------- -----------
Total expenses 5,903,705 4,319,729
Operating loss (2,033,839) (2,618,494)
Other income (expense)
Interest income 247,689 90,215
Interest expense (138,039) (112,091)
Equity in loss of unconsolidated affiliate (1,797,826) (494,624)
----------- -----------
Total other income (expense) (1,688,176) (516,500)
Net loss $(3,722,015) $(3,134,994)
=========== ===========
Net loss per share $(0.31) $(0.34)
Shares used in computing net loss per share 11,875,081 9,182,095
=========== ===========
</TABLE>
See notes to condensed financial statements
4
<PAGE>
RIBOZYME PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
Three months ended
March 31,
---------------------------
2000 1999
------------ -----------
Operating Activities
Net loss $ (3,722,015) $(3,134,994)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization 442,043 416,649
Equity in loss of unconsolidated affiliates 1,797,826 494,624
Compensation related to common stock and
options 681,133 -
Compensation for forgiveness of notes
receivable-related parties 42,466 52,466
Accrued interest included in convertible debt 137,322 82,917
Changes in operating assets and liabilities:
Accounts receivable (1,633,425) 398,809
Prepaid expenses and other current assets (317,663) (39,438)
Other assets - 2,925
Accounts payable-trade 568,129 777,301
Accrued expenses 131,872 (74,984)
Deferred revenue-related parties (99,998) (100,001)
------------ -----------
Net cash used in operating activities (1,972,310) (1,123,726)
Investing activities
Additions to property, plant and equipment (163,370) (413,124)
Additions to deferred patent costs (165,632) (46,921)
Net sales (purchases) of securities
available-for-sale 3,153,491 (996,611)
Investment in unconsolidated affiliate (12,015,000) -
Loan advances-related parties - (35,000)
------------ -----------
Net cash used in investing activities (9,190,511) (1,491,656)
Financing activities
Net proceeds from sale of common and preferred
stock 17,474,379 5,018
Payments under loan facilities (107,973) (95,869)
Borrowings under loan facilities 1,000,000 1,000,000
------------ -----------
Net cash provided by financing activities 18,366,406 909,149
Net increase (decrease) in cash and cash
equivalents 7,203,585 (1,706,233)
Cash and cash equivalents at beginning of period 9,749,822 6,511,512
------------ -----------
Cash and cash equivalents at end of period $ 16,953,407 $ 4,805,279
============ ===========
See notes to condensed financial statements.
5
<PAGE>
RIBOZYME PHARMACEUTICALS, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
March 31, 2000
(Unaudited)
Note 1: Basis of Presentation
The accompanying unaudited condensed financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair presentation have
been included. Operating results for the three-month period ending March 31,
2000 are not necessarily indicative of the results that may be expected for the
year ended December 31, 2000. For further information, refer to the financial
statements and footnotes thereto included in our annual report on Form 10-K
for the year ended December 31, 1999.
Note 2: Medizyme
In January 2000, we completed formation of a joint venture with Elan
Corporation plc (Elan) whereby we have licensed HERZYME(TM), a potential product
to treat breast and other cancers, and Elan licensed its MEDIPAD(R) drug
delivery technology to the joint venture, Medizyme Pharmaceuticals, Ltd.
(Medizyme). The MEDIPAD(R) system is a multi-day disposable continuous
subcutaneous drug delivery system that allows a patient to administer the drug
at home.
Initial funding of Medizyme included $12.0 million from us and $3.0 million
from Elan. Our $12.0 million capital contribution was funded by the sale to
Elan of (i) 12,015 shares of our Series A convertible exchangeable preferred
stock (the Series A Preferred Stock), (ii) a warrant to purchase up to 200,000
shares of our common stock at an exercise price of $15.00 per share with a term
of two years, and (iii) a warrant to purchase up to 300,000 shares of our common
stock at an exercise price of $20.00 per share with a term of seven years. The
Series A Preferred Stock has a stated dividend rate of 6.0% which is payable
semi-annually through the issuance of additional shares of Series A Preferred
Stock at a nominal value of $1,000 per share.
As a result of Medizyme's initial capitalization, we own 80.1% of the
outstanding capital stock of Medizyme and Elan owns 19.9%. However, Elan can
exchange, at its option, all of its shares of our Series A preferred stock for
30.1% of RPI's interest in Medizyme. After such redemption, Elan would own 50%
of the then outstanding capital stock of Medizyme. Elan also has the option of
converting its shares of our Series A Preferred Stock into approximately
1,200,000 shares of our common stock.
Medizyme paid Elan in cash a $15.0 million non-refundable license fee for
the MEDIPAD(R) drug delivery technology. As a result of this licensing
transaction, Medizyme has capitalized the entire license fee and is amortizing
the balance over the three-year term of the agreement. We estimate that funding
for Medizyme will require approximately $15.0 million in additional operating
and development costs. In connection with expected funding requirements, Elan
has agreed to provide us with a $12.0 million credit facility to fund our pro
rata portion of Medizyme's operating costs over the development period, which is
expected to be 30 months. The debt has a 12% rate and may be converted into
shares of our Series B convertible preferred stock, which ultimately is
convertible into shares of our common stock at a 50% premium to the average
price of our common stock for the 60 days prior to the time of the applicable
draw down on the credit facility. The Series B convertible preferred stock has a
stated dividend rate of
6
<PAGE>
12%, which is payable semi-annually through the issuance of additional shares of
Series A Preferred Stock at a nominal value of $1,000 per share.
Also in connection with the Medizyme joint venture, Elan purchased 641,026
shares of our common stock for a purchase price of $5.0 million. Elan has
committed to purchase an additional $5.0 million of common stock in April 2001
at a share price that is at a premium to the average closing price for the 45
trading days preceding the purchase, but not less than such 45 trading day
average. The price is also based on the achievement of certain milestones.
The joint venture agreement provides for equal representation by us and
Elan in the operating and management decisions of Medizyme. We account for our
investment in Medizyme under the equity method.
Note 3: Subsequent Event-Public Offering
In April 2000, we completed a public offering of 3,150,000 shares of our
common stock that resulted in gross proceeds of $56.7 million. After underwriter
fees and expenses are deducted, net proceeds are expected to be approximately
$52.7 million. In April 2000 we repaid $6.9 million of our outstanding
borrowings from Schering AG with proceeds from this offering.
7
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
Overview of our Business
We are developing a new class of drugs based on engineered molecules called
"ribozymes." Ribozymes are a form of ribonucleic acid which have the ability to
cleave RNA, including mRNA, and thereby selectively inhibit protein production.
Because many human diseases result from abnormal protein production, we believe
that ribozymes are applicable to a broad range of human diseases. We are
currently in clinical development and preclinical testing for three product
candidates and expect to begin preclinical testing on one additional product
candidate by the end of 2000.
We are conducting a Phase I/II clinical trial for our lead product
candidate, ANGIOZYME(TM), for the treatment of solid tumor cancers in
collaboration with Chiron Corporation and expect to complete this trial before
the end of 2000. Also, clinical trials for our anti-HCV ribozyme for the
treatment of Hepatitis C have been initiated with Eli Lilly and Company.
In January 2000, we announced completion of a joint venture with Elan
Corporation, Medizyme Pharmaceuticals, Ltd., whereby we have licensed
HERZYME(TM) and Elan has licensed its MEDIPAD(R) technology to the joint
venture. MEDIPAD(R) is a multi-day disposable continuous subcutaneous drug
delivery system that allows a patient to administer the drug at home. Initial
funding of Medizyme included $12.0 million from us and $3.0 million from Elan.
Currently, we own 80.1% of Medizyme's capital stock and Elan owns 19.9%. We
have estimated that funding for Elan will require approximately $15.0 million in
additional operating and development costs and, therefore, Elan has provided us
with a $12.0 million credit facility on a draw-down basis for us to use, if
desired, to fund our portion of Medizyme operating costs over a 30 month period.
The debt has a 12% rate and may ultimately be converted into our common stock at
a 50% premium.
To date, we have committed substantially all our resources to our research
and product development programs. We have not generated any revenues from
product sales, nor do we anticipate any in the foreseeable future. Revenue
recorded from our collaborative agreements consists of:
. Up front revenue. Up front revenue is fully recognized upon signing a
collaboration and is related to the value of the research at that point in
time. Up front revenue may also be a reimbursement to us of recent expenses
which we incurred related to product development. All up front revenues
recognized represents the culmination of a separate earnings process.
. Research revenue. Typically research revenue is based on the fully burdened
cost of a researcher working on a collaboration. Rates are billed per
employee, per year, prorated for time worked on a project. This revenue is
typically invoiced on a quarterly basis, either up front or in arrears.
Revenue is recognized ratably over the period, with the balance reflected
as deferred revenue until earned. The revenue is typically recurring over
the term of a collaboration.
. License revenue. License revenue is recognized ratably over the term of the
license. Payments received in advance are recorded as deferred revenue
until earned.
. Milestone revenue. Milestone revenue is recognized in full when the related
milestone performance goal is achieved. Milestone revenue is typically not
consistent or recurring in nature.
8
<PAGE>
Our revenue has consisted primarily of research revenue payments from our
collaborators. All revenues are either deferred as a liability or recognized
upon satisfying revenue criteria. As of March 31, 2000, all revenues that have
been recognized are earned and no further obligations exist for recognized
revenue. We depend upon funding from external financing and corporate
collaborations for our research and product development programs and expect to
do so for the foreseeable future.
We have not been profitable since inception and have an accumulated deficit
of $87.8 million as of March 31, 2000. Losses have resulted primarily from our
research and development programs. We expect to incur additional losses as
ANGIOZYME(TM), the anti-HCV ribozyme, HERZYME(TM), and other product candidates
advance through development. In addition, future milestone payments under some
of our collaborations are contingent upon our meeting particular research or
development goals. The amount and timing of future milestone payments are
contingent upon the terms of each collaboration agreement. In some instances, we
may forfeit milestone payments if we fail to accomplish a goal within a certain
time frame. Therefore, we are subject to significant variation in the timing and
amount of our revenues and results of operations from period to period.
In 1998, we transferred our target discovery and validation technology to
Atugen Biotechnology AG in exchange for a substantial equity interest. We will
continue our existing target discovery and validation agreements with our
collaborators by subcontracting services to be performed to Atugen. We currently
own 48.4% of Atugen and will record our share of any future profits. In 1999,
through the absorption of equity in the losses of Atugen, we eliminated our
remaining investment in Atugen.
Our revenues are denominated in U.S. dollars, therefore, we have not been
exposed to foreign currency translation risks and have not engaged in any
hedging instruments.
Results of Operations
Three Months Ended March 31, 2000 and 1999
Collaborative revenues increased to $3.9 million for the three months ended
March 31, 2000, from $1.7 million for the corresponding period in 1999. The
increase is primarily due to $1.1 million in revenues recorded from Eli Lilly
related to joint product development of the anti-HCV ribozyme and $972,000 in
revenues recorded from Medizyme, our joint venture with Elan for the preclinical
development of HERZYME(TM), a ribozyme targeted at breast and other cancers.
Both the Eli Lilly and Elan collaborations did not exist in the first quarter of
1999. In 1999, first quarter revenues consisted of $1.1 million in research
revenues from Chiron and $593,000 in revenues for services provided to Atugen.
The revenues from Eli Lilly during the first quarter of 2000 include a $500,000
milestone payment for having filed the Investigational New Drug (IND)
application with the FDA for the anti-HCV ribozyme. Revenues in the first
quarter of 2000 also include research revenues of $1.4 million, $618,000 and
$972,000 from Chiron, Eli Lilly and Medizyme, respectively. According to the
Chiron agreement, Chiron and RPI share equally in the clinical trial costs of
ANGIOZYME(TM) and for the first quarter of 2000 we incurred the majority of
expenses related to ANGIOZYME(TM) development. Research revenue is for expenses
already incurred and no further obligation exists between us and our partners
for revenues recognized. Future research revenues related to the joint
development of our products will be variable and will depend on the stage of
research and preclinical and clinical development. In addition, during the
first quarter of 2000, $358,000 in revenue was recorded in connection to our
service agreement with Atugen. Atugen pays for reagents and management and
administrative services we provide. Atugen revenues are earned by us as the
products and services are provided. Both Atugen and Medizyme are related
parties. Future revenues will depend on the level of activities performed by
us. Generally,
9
<PAGE>
revenue fluctuations result from changes in the number of funded research
projects as well as the timing and completion of contract milestones.
Research and development expenses increased to $4.9 million for the three
months ended March 31, 2000, compared to $3.8 million for the corresponding
period in 1999. The increase was due to approximately $261,000 of a non-cash,
stock option compensation expense recorded for performance stock options that
vested during the first quarter of 2000. During the first quarter, a number of
research and development milestones were achieved, including filing the IND and
commencing Phase I for the anti-HCV ribozyme, as well as starting pre-clinical
development of HERZYME(TM). Accounting rules require that the difference
between an option grant price and the market price must be expensed as
compensation for performance related stock options. During the first quarter of
2000, our stock price achieved considerable highs on dates when performance
options vested, resulting in significant non-cash stock compensation expense.
In addition, increased expenses for the first quarter of 2000 included
approximately $280,000 of expenses related to increased staffing. The increase
from 1999 was also due to an increase of approximately $313,000 for clinical
trial expenses related to ANGIOZYME(TM) and research expenses relating to the
anti-HCV ribozyme. Other expenses have increased accordingly, due to increased
staffing and the expansion of our development programs. We expect research and
development expenses, including pre-clinical studies and clinical trials, to
continue to increase as we expand our development programs for ANGIOZYME(TM),
the anti-HCV ribozyme and HERZYME(TM).
General and administrative expenses increased to $1.0 million for the three
months ended March 31, 2000, compared to $559,000 for the corresponding period
in 1999. The increase was primarily due to approximately $420,000 of non-cash,
stock option compensation expense recorded for performance stock options that
vested during the first quarter of 2000. During the first quarter, a number of
corporate milestones were accomplished, including achieving a market
capitalization of $150 million or more and a number of other financial goals
which were satisfied by the consummation of the Elan agreement. Additional
increases are the result of increased expenses necessary to manage and support
our expanding product and business development efforts. We expect general and
administrative expenses to continue to increase as a result of increasing legal
and other professional fees in connection with the overall scale-up of our
operations, business development efforts and patent protection.
Interest income increased to $248,000 for the three months ended March 31,
2000 compared to $90,000 for the corresponding period in 1999. The increase is
due to higher average balances in our cash and cash equivalents and securities
available-for-sale during the first quarter of 2000, as compared to the same
quarter in 1999. Cash balances were higher as a result of a public offering
completed in July 1999 that resulted in $5.3 million net proceeds and $5.0
million received in January 2000 for the sale of common stock to Elan upon the
signing of the collaboration. Interest income generally fluctuates as a result
of the average amount of cash available for investment and prevailing interest
rates.
Interest expense increased to $138,000 for the three months ended March 31,
2000 compared to $112,000 for the corresponding period in 1999. The increase is
due to additional loan draw downs of $2.0 million during 1999 and the resulting
compounding interest accrued for the period.
Equity in loss of unconsolidated affiliate was $1.8 million for the period
ending March 31, 2000, compared to $495,000 for the corresponding period in
1999. The expense for the first quarter in 2000 is our 80.1% share of
Medizyme's first quarter expenses. Our ownership in the Medizyme joint venture
is 80.1% and as such we are required to expense our share of their losses.
Medizyme's first quarter expenses include $1.25 million amortized expense for
payment of a $15.0 million license fee paid to Elan in January 2000 and $972,000
we invoiced for research we conducted on HERZYME(TM). The 1999 equity in loss
of unconsolidated affiliate expense was in connection with our initial cash
investment of
10
<PAGE>
$2.0 million and the subsequent transfer of our gene identification and target
validation technology to Atugen AG in 1998. At March 31, 1999, we owned 83.2% of
Atugen's outstanding common stock and, as a result, we recorded our share of
Atugen's first quarter net loss resulting in equity in loss of unconsolidated
affiliate of $495,000. In 1999, we completely expensed our remaining investment
in Atugen and therefore no expense related to Atugen was recorded during the
first quarter of 2000.
Liquidity and Capital Resources
We have financed our operations since inception through sales of equity
securities in public offerings, private placements of preferred and common
stock, funds received under our collaborative agreements and financing under
equipment and tenant improvement loans. From inception through March 31, 2000,
we have received approximately:
. $29.0 million in net proceeds from private placements;
. $36.4 million in net proceeds from public offerings;
. $78.2 million from our collaborations; and
. $9.8 million from equipment financing.
We had cash, cash equivalents and securities available-for-sale of $18.1
million at March 31, 2000 compared with $14.0 million at December 31, 1999. The
$4.1 million increase in cash, cash equivalents and securities available-for-
sale is primarily the result of $2.0 million used for operations, net of
revenues of $3.9 million and $329,000 used for investments in equipment and
patents, offset by:
. $17 million received in a sale of preferred and common stock to a corporate
collaborator;
. $12.0 million invested in Medizyme;
. $1.0 million in net borrowings;
. $494,000 received for sales of common stock under option exercises; and
. $108,000 for payments on loan facilities.
We invest our cash, cash equivalents and securities available-for-sale in
interest-bearing, investment grade securities.
Accounts receivable at March 31, 2000 were $3.7 million compared to $2.0
million at December 31, 1999. Accounts receivable at March 31, 2000 included
$1.5 million due from Chiron for reimbursement of ANGIOZYME(TM) first quarter
research, $972,000 due from Medizyme for first quarter HERZYME(TM) research,
$607,000 due from Eli Lilly for research support in the first quarter for our
anti-HCV ribozyme program and $505,000 due from Atugen for administrative
services and patent expenses. Accounts receivable at December 31, 1999
primarily consisted of $485,000 due from Atugen for administrative services and
patent expenses, $525,000 due from Eli Lilly for research support for our anti-
HCV ribozyme program and $1.0 million due from Chiron for reimbursement of
ANGIOZYME(TM) fourth quarter research. The majority of outstanding receivables
due from 1999 have been received in 2000.
Total additions for property, plant and equipment for the three months
ending March 31, 2000 were $163,000, most of which were financed through our
existing equipment loan facility with Schering AG, described below. We
anticipate future capital needs to be financed by the Schering AG loan facility
for the next two years.
As part of our target discovery and validation program, Schering AG made a
$2.5 million equity investment in us in May 1997 in exchange for 212,766 shares
of common stock and made an additional
11
<PAGE>
equity investment of $2.5 million for 465,117 shares in April 1998. Separately,
Schering AG provided loans of $2.0 million in each of 1997, 1998 and 1999 and
$1.0 million in February 2000. Schering AG is expected to continue to provide
loans of up to $2.0 million annually through 2001, provided that the
collaboration is continued. In April 2000, after the completion of a public
offering, we repaid $6.9 million of our outstanding borrowings from Schering AG.
If Schering AG does not continue the collaboration, we may need to seek
alternative sources of financing. Amounts not used in any calendar year may be
carried forward to future years. According to the terms of our agreement with
Schering AG, 50.0% of any borrowings on the line of credit must be
collateralized by equipment purchases. The loans, which carry an interest rate
of 8.0% per annum, are immediately convertible into equity at the option of
Schering AG. At March 31, 2000, the outstanding borrowings of $7.9 million were
convertible into approximately 314,000 shares of our common stock. Principal and
interest payments are deferred until maturity of the loans in April 2004. As a
result of the Atugen formation in 1998, we now subcontract all of our existing
target discovery and identification programs to Atugen; however, as long as our
collaboration continues with Schering AG we expect to continue to borrow against
the loans.
In July 1994, we entered into an agreement with Chiron to collaborate
exclusively on up to five specific targets selected by Chiron. Four targets are
currently subject to the exclusivity provision, including ANGIOZYME(TM).
Currently, ANGIOZYME(TM) is being developed in collaboration with Chiron and we
share equally all development costs and profits with Chiron. In 1999, we
recorded $4.0 million in revenues due from Chiron for reimbursement of expenses
incurred for the clinical development of ANGIOZYME(TM). During the first
quarter of 2000, we recorded $1.4 million in revenues due from Chiron for
ANGIOZYME(TM). We expect total 2000 expenses related to ANGIOZYME(TM) to be
approximately $11.0 million, of which Chiron is expected to reimburse us
approximately $5.5 million.
In March 1999, we entered into a collaboration with Eli Lilly to conduct
research, development and commercialization of our anti-HCV ribozyme for the
treatment of Hepatitis C virus infection. We granted Eli Lilly the exclusive
worldwide right to develop and commercialize the anti-HCV ribozyme in return for
funding of all research, development and commercialization costs for the drug.
Under the terms of the agreement, we received approximately $9.2 million during
1999, which included $1.7 million of funding for research and clinical trial
expenses and a $7.5 million equity investment. In April 1999, Eli Lilly
purchased five shares of our Series L convertible preferred stock for $7.5
million. Each share of Series L convertible preferred stock is convertible into
shares of our common stock based upon milestones related to the development and
commercialization of the anti-HCV ribozyme. Depending on the achievement of
certain milestones, each share of convertible preferred stock will either
convert into $500,000 or $1.5 million of common stock valued at the average
closing price over the 30 days prior to conversion. During the first quarter of
2000, we recorded $1.1 million in revenues due from Eli Lilly, which included
$618,000 in research revenues and a $500,000 milestone payment for the IND
filing of the anti-HCV ribozyme. In 2000, we expect to receive approximately
$2.9 million for research in addition to the milestone payment of $500,000 for
the filing of the IND.
In January 2000, we completed a joint venture with Elan for the development
and commercialization of HERZYME(TM), our potential product to treat breast and
other cancers. In accordance with the collaboration, we sold to Elan our Series
A convertible preferred stock for $12.0 million and, in turn, used those funds
for initial funding of Medizyme. Also as part of the collaboration, Elan
purchased 641,026 shares of our common stock for a purchase price of $5.0
million. Elan has also committed to purchase an additional $5.0 million of
common stock in April 2001 at a share price that is at a premium to the then
market price and would also be based on the achievement of certain milestones.
We have estimated that the development of HERZYME(TM) will require additional
funds of up to $15 million and, therefore, Elan has made available to us a
credit facility to use to fund our portion of Medizyme operating costs over a 30
month period. Elan may convert this debt into shares of our Series B
12
<PAGE>
convertible preferred stock in the future. During the first quarter of 2000, we
recorded revenues due from Medizyme of $972,000 for research conducted for the
development of HERZYME(TM). In 2000, we expect to receive approximately $3.9
million in research revenues from Medizyme relating to our work on HERZYME(TM)
development.
In April 2000, we completed a public offering of 3,150,000 shares of our
common stock that resulted in gross proceeds of $56.7 million. After underwriter
fees and expenses are deducted, net proceeds are expected to be approximately
$52.7 million. In April 2000 we repaid $6.9 million of our outstanding
borrowings from Schering AG with proceeds from this offering.
We anticipate that the net proceeds from our offering, together with our
existing financial resources and expected revenues from our collaborations,
should be sufficient to meet our anticipated operating and capital requirements
through 2002. We expect to incur substantial additional costs, including:
. costs related to our research, drug discovery and development programs;
. preclinical studies and clinical trials of our products, if developed;
. prosecuting and enforcing patent claims;
. general administrative and legal items; and,
. manufacturing and marketing of products, if any.
In the future we may raise additional capital through public or private
financing, as well as from new collaborative relationships, new credit
facilities and other sources.
Impact of Year 2000
In our 1999 public filings, we discussed the nature and progress of our
plans to become Year 2000 ready. In late 1999, we completed our remediation and
testing of systems. As a result of those planning and implementation efforts, we
experienced no significant disruptions in mission critical information
technology and non-information technology systems and we believe those systems
successfully responded to the Year 2000 date change. We expensed approximately
$60,000 during 1999 in connection with remediating our systems. We are not aware
of any material problems resulting from Year 2000 issues, either with our
research, internal systems or the products and services of third parties. We
will continue to monitor our mission critical computer applications and those of
our suppliers and vendors throughout the year 2000 to ensure that any latent
Year 2000 matters that may arise are addressed promptly.
Forward-looking Statements
Statements in this Form 10-Q, which are not strictly historical, are
"forward-looking" statements which should be considered as subject to the many
uncertainties that exist in our operations and business environment. These
uncertainties, which include, among other things, the following: general
economic and business conditions; competition; technological advances; ability
to obtain rights to technology; ability to obtain and enforce patents; ability
to commercialize and manufacture products; ability to obtain collaborators;
ability to manufacture ribozymes in adequate amounts for its collaborations and
clinical trials; results of clinical studies; results of research and
development activities; business abilities and judgment of personnel;
availability of qualified personnel; changes in, or failure to comply with,
governmental regulations; ability to obtain adequate financing in the future;
and the like, are set forth in our 10-K for the year ended December 31, 1999
which is on file with the U.S. Securities and Exchange Commission, a copy of
which is available from us.
13
<PAGE>
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
3(i) Amended and Restated Certificate of Incorporation (1)
3(ii) Restated Bylaws (2)
27 Financial Data Schedule
(b) Reports on Form 8-K
We filed a report on Form 8-K dated February 8, 2000, which reported a
joint venture agreement dated January 7, 2000 with Elan Corporation, plc
and various of its affiliates (collectively, "Elan") to develop and
commercialize our ribozyme HERZYME(TM) against Human Epidermal Growth
Factor Receptor Type 2 for treatment of breast and other cancers using
Elan's proprietary MEDIPAD(R) drug delivery system. This joint venture was
accomplished through the formation of Medizyme Pharmaceuticals Ltd., a
Bermuda limited liability company. In addition, the Form 8-K reported a
manufacturing agreement dated January 31, 2000 with Avecia Limited
(Avecia), acting through its LifeScience Molecules business. Pursuant to
the agreement, we transferred proprietary manufacturing processes and
intellectual property to Avecia.
______
(1) Incorporated by reference from the Company's Registration Statement on Form
SB-2, file no. 333-34981, dated September 5, 1997.
(2) Incorporated by reference from the Company's Registration Statement on Form
SB-2, file no. 333-1908-D, dated April 11, 1996.
14
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
RIBOZYME PHARMACEUTICALS, INC.
Dated: May 12, 2000 By: /s/ RALPH E. CHRISTOFFERSEN
------------ ----------------------------
Ralph E. Christoffersen
President and Chief
Executive Officer
Dated: May 12, 2000 By: /s/ LAWRENCE E. BULLOCK
------------ ----------------------------
Lawrence E. Bullock
Vice President and Chief Financial Officer
(Principal Financial Officer and
Principal Accounting Officer)
15
<PAGE>
Exhibit Index
Exhibit Exhibit
No. Description
- ------- -----------
3(i) Amended and Restated Certificate of Incorporation (1)
3(ii) Restated Bylaws (2)
27 Financial Data Schedule
_____
(1) Incorporated by reference from the Company's Registration Statement on Form
SB-2, file no. 333-34981, dated September 5, 1997.
(2) Incorporated by reference from the Company's Registration Statement on Form
SB-2, file no. 333-1908-D, dated April 11, 1996.
16
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF RIBOZYME PHARMACEUTICALS, INC. FOR THE THREE MONTHS
ENDED MARCH 31, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<CASH> 16,953,407
<SECURITIES> 1,097,466
<RECEIVABLES> 3,663,318
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 22,288,425
<PP&E> 12,415,160
<DEPRECIATION> 8,856,055
<TOTAL-ASSETS> 41,155,646
<CURRENT-LIABILITIES> 2,792,945
<BONDS> 0
0
120
<COMMON> 120,115
<OTHER-SE> 29,194,604
<TOTAL-LIABILITY-AND-EQUITY> 41,155,646
<SALES> 0
<TOTAL-REVENUES> 3,869,866
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 4,864,835
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 138,039
<INCOME-PRETAX> (3,722,015)
<INCOME-TAX> 0
<INCOME-CONTINUING> (3,722,015)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (3,722,015)
<EPS-BASIC> (0.31)
<EPS-DILUTED> (0.31)
</TABLE>
